Taking thalidomide out of rehab.
作者信息
Akhurst Rosemary J
出版信息
Nat Med. 2010 Apr;16(4):370-2. doi: 10.1038/nm0410-370.
Abstract
摘要
相似文献
1
Taking thalidomide out of rehab.
Nat Med. 2010 Apr;16(4):370-2. doi: 10.1038/nm0410-370.
2
Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia.
Nat Med. 2010 Apr;16(4):420-8. doi: 10.1038/nm.2131. Epub 2010 Apr 4.
3
Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life.
Turk J Haematol. 2019 Feb 7;36(1):43-47. doi: 10.4274/tjh.galenos.2018.2018.0190. Epub 2018 Jun 8.
4
Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study.
Otolaryngol Head Neck Surg. 2017 Aug;157(2):217-221. doi: 10.1177/0194599817700573. Epub 2017 Apr 18.
5
Thalidomide for hereditary haemorrhagic telangiectasia.
Lancet Haematol. 2015 Nov;2(11):e457-8. doi: 10.1016/S2352-3026(15)00222-7. Epub 2015 Oct 27.
6
Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia.
Blood Coagul Fibrinolysis. 2011 Oct;22(7):616-8. doi: 10.1097/MBC.0b013e32834a040c.
7
The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.
J Laryngol Otol. 2018 Oct;132(10):866-871. doi: 10.1017/S0022215118001536. Epub 2018 Sep 7.
8
Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.
Lancet Haematol. 2015 Nov;2(11):e465-73. doi: 10.1016/S2352-3026(15)00195-7. Epub 2015 Oct 27.
9
Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.
Thromb Haemost. 2007 Feb;97(2):254-62.
10
Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide.
Med Hypotheses. 2013 May;80(5):587-8. doi: 10.1016/j.mehy.2013.01.031. Epub 2013 Feb 27.
引用本文的文献
1
The maternal drug exposure birth cohort (DEBC) in China.
Nat Commun. 2024 Jun 21;15(1):5312. doi: 10.1038/s41467-024-49623-0.
2
Targeting the microenvironment in the treatment of arteriovenous malformations.
Angiogenesis. 2024 Feb;27(1):91-103. doi: 10.1007/s10456-023-09896-3. Epub 2023 Sep 21.
3
Functional Validation of Osteoporosis Genetic Findings Using Small Fish Models.
Genes (Basel). 2022 Jan 30;13(2):279. doi: 10.3390/genes13020279.
4
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.
Oncoscience. 2015 Mar 2;2(2):193-204. doi: 10.18632/oncoscience.136. eCollection 2015.
5
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.
Ther Adv Hematol. 2011 Oct;2(5):291-308. doi: 10.1177/2040620711413165.
6
Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview.
Future Microbiol. 2011 Feb;6(2):217-30. doi: 10.2217/fmb.10.173.
本文引用的文献
1
Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia.
Nat Med. 2010 Apr;16(4):420-8. doi: 10.1038/nm.2131. Epub 2010 Apr 4.
2
Thalidomide-induced limb defects: resolving a 50-year-old puzzle.
Bioessays. 2009 Dec;31(12):1327-36. doi: 10.1002/bies.200900103.
3
Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.
Liver Transpl. 2008 Feb;14(2):210-3. doi: 10.1002/lt.21417.
4
Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.
Ann Hematol. 2006 Sep;85(9):631-2. doi: 10.1007/s00277-006-0147-8. Epub 2006 Jun 29.
5
Genetic loci that control vascular endothelial growth factor-induced angiogenesis.
FASEB J. 2003 Nov;17(14):2112-4. doi: 10.1096/fj.03-0246fje. Epub 2003 Sep 4.
6
Gap junction communication mediates transforming growth factor-beta activation and endothelial-induced mural cell differentiation.
Circ Res. 2003 Sep 5;93(5):429-37. doi: 10.1161/01.RES.0000091259.84556.D5. Epub 2003 Aug 14.
7
Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.
Anticancer Res. 2003 May-Jun;23(3B):2481-7.
8
Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice.
Hum Mol Genet. 2003 Jul 1;12(13):1579-89. doi: 10.1093/hmg/ddg164.
9
Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia.
Am J Pathol. 2001 Jun;158(6):2011-20. doi: 10.1016/s0002-9440(10)64673-1.
10
Genetic heterogeneity of angiogenesis in mice.
FASEB J. 2000 May;14(7):871-6. doi: 10.1096/fasebj.14.7.871.
Zotero 插件